Celera and Medco Enter Research Collaboration to Evaluate Effect of KIF6 Testing on Compliance with Statin Therapy in Patients with Cardiovascular Disease
External link:*
http://medco.mediaroom.com/index.php?s=43&item=397 Celera Corporation and Medco Health Solutions, Inc. announced that they have entered into a research collaboration to evaluate whether testing for a gene variant called KIF6 increases patient adherence with statin therapy.
Author: Medco and Celera
Related numbers to fix:
$475 Billion 
